MF59 trivalent subunit influenza vaccine

The **MF59 trivalent subunit influenza vaccine** is an inactivated, egg-derived influenza vaccine formulated to protect against three influenza virus strains: two influenza A subtypes (typically H1N1 and H3N2) and one influenza B lineage[1][6]. It contains the **MF59 adjuvant**, an oil-in-water emulsion of squalene, which enhances immune response primarily by recruiting immune cells to the injection site and promoting both Th1 and Th2 responses[1][4]. This vaccine is approved for use in adults 65 years and older and marketed under brand names such as **Fluad** and **VANTAFLU**[2][1]. Clinical trials show it induces higher and broader immune responses and is more immunogenic than non-adjuvanted alternatives in older adults[2][4]. The vaccine is used for the prevention of seasonal influenza and has an established safety profile, with the most common adverse events being mild and transient, such as injection site pain, muscle aches, and headache[1][2]. The MF59 trivalent vaccine is also the first adjuvanted seasonal influenza vaccine approved in the U.S.[1].

Brand names

FluadVANTAFLU

Other names

MF59-adjuvanted trivalent inactivated subunit influenza vaccineMF-59-adjuvanted trivalent inactivated subunit influenza vaccineMF 59-adjuvanted trivalent inactivated subunit influenza vaccineMF59 trivalent influenza vaccineMF-59 trivalent influenza vaccineMF 59 trivalent influenza vaccineMF59-adjuvanted influenza vaccineMF-59-adjuvanted influenza vaccineMF 59-adjuvanted influenza vaccine